These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35869309)

  • 1. Long-acting agents for HIV treatment and prevention.
    Bekker LG
    Nat Med; 2022 Aug; 28(8):1542-1543. PubMed ID: 35869309
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
    Landovitz RJ; Grinsztejn B
    J Infect Dis; 2016 May; 213(10):1519-20. PubMed ID: 26681779
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting injectable for HIV approved for use in the UK.
    Kirby T
    Lancet Infect Dis; 2022 Jan; 22(1):26. PubMed ID: 34953553
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equitable access to long-acting PrEP on the way?
    The Lancet Hiv
    Lancet HIV; 2022 Jul; 9(7):e449. PubMed ID: 35777403
    [No Abstract]   [Full Text] [Related]  

  • 6. Pre-Exposure Prophylaxis for HIV Prevention.
    Fadul N
    N C Med J; 2016; 77(5):361-2. PubMed ID: 27621351
    [No Abstract]   [Full Text] [Related]  

  • 7. Preexposure Prophylaxis: Adapting HIV Prevention Models to Achieve Worldwide Access.
    Landers S; Kapadia F
    Am J Public Health; 2017 Oct; 107(10):1534-1535. PubMed ID: 28902562
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiretrovirals for HIV prevention: when should they be recommended?
    Kiselinova M; De Spiegelaere W; Verhofstede C; Callens SF; Vandekerckhove L
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):431-45. PubMed ID: 24621251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PrEP for HIV prevention, major tool of the global diversified prevention strategy].
    Slama L
    Rev Prat; 2021 Nov; 71(9):957-959. PubMed ID: 35147307
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure prophylaxis in-pocket).
    Wood BR
    AIDS; 2020 Mar; 34(3):481-482. PubMed ID: 31996596
    [No Abstract]   [Full Text] [Related]  

  • 12. The Path to Implementation of HIV Pre-exposure Prophylaxis for People Involved in Criminal Justice Systems.
    Brinkley-Rubinstein L; Dauria E; Tolou-Shams M; Christopoulos K; Chan PA; Beckwith CG; Parker S; Meyer J
    Curr HIV/AIDS Rep; 2018 Apr; 15(2):93-95. PubMed ID: 29516265
    [No Abstract]   [Full Text] [Related]  

  • 13. Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance.
    Raccagni AR; Bruzzesi E; Gianotti N; Sampaolo M; Canetti D; Castagna A; Nozza S
    Sex Transm Infect; 2022 May; 98(3):234. PubMed ID: 35039436
    [No Abstract]   [Full Text] [Related]  

  • 14. Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use.
    Siegler AJ
    Clin Infect Dis; 2021 Feb; 72(3):386-387. PubMed ID: 33527116
    [No Abstract]   [Full Text] [Related]  

  • 15. More pre-exposure prophylaxis for rising HIV infection?
    Barreiro P
    AIDS Rev; 2014; 16(2):118-9. PubMed ID: 24984768
    [No Abstract]   [Full Text] [Related]  

  • 16. Pre-exposure prophylaxis for HIV: effective and underused.
    Hempel A; Biondi MJ; Baril JG; Tan DHS
    CMAJ; 2022 Sep; 194(34):E1164-E1170. PubMed ID: 36265058
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Ibrahim ME; Glidden DV; Grant RM; Anderson PL
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):407-408. PubMed ID: 33913746
    [No Abstract]   [Full Text] [Related]  

  • 18. Updates in pre-exposure prophylaxis for HIV.
    Mushtaq A; Kazi F
    Lancet Infect Dis; 2022 Mar; 22(3):320. PubMed ID: 35218750
    [No Abstract]   [Full Text] [Related]  

  • 19. Reaching the full preventive potential of HIV pre-exposure prophylaxis.
    Coyer L; Hoornenborg E
    Lancet Public Health; 2022 Jun; 7(6):e488-e489. PubMed ID: 35660206
    [No Abstract]   [Full Text] [Related]  

  • 20. Ending sexual HIV transmission: lessons learned from perinatal HIV.
    Weber S; Grant RM
    J Assoc Nurses AIDS Care; 2015; 26(5):520-5. PubMed ID: 26096627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.